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Introduction: just recently, it has been established that the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism is linked 
to the pathogenesis and to the evolution of human cancers. Therefore, the present study was concerned with the investigation of an eventual 
association between glioma and I/D polymorphism of the ACE gene. Methods: the expression of ACE gene was detected by polymerase chain 
reaction restriction fragment length polymorphism (PCR-RFLP) analysis in 36 Algerian patients with glioma and 195 healthy controls. Results: in 
glioma cases, allelic frequencies and genotypes distribution of the ACE I/D polymorphism were different from controls cases. ACE DD genotype were 
highly presented in glioma cases (63.9%) than controls (33.8%) and conferred 3.64-fold risk for predisposition in glioma cases (vs ID genotype, 
p<0.001). Recessive model (ACE II + ID genotypes vs DD) was associated with a 72% reduced risk of glioma (OR = 0.28, 95% CI: 0.13-0.60, p 
<0.001). Per copy D allele frequency was found higher in glioma cases (79.2%) than in controls (63.3 %), OR = 2.20, 95% CI: 1.20 - 4.03, p = 
0.009. Conclusion: the obtained data showed that the presence of the D allele might be a risk factor for the development of glioma. Further studies 
considering different ethnic groups with large samples are required to confirm this finding. 
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Gliomas are the most common primary intraparenchymal tumors of 
the central nervous system (CNS) with a very poor prognosis. They 
represent approximately 26% of all primary brain and other CNS 
tumors and 81% of the malignant tumors. Glioblastoma accounts for 
the majority of gliomas (56.6%). Relative survival estimates for 
glioblastoma are quite low with only 5.6% of patients who survived 
five years post diagnosis [1] . Historically gliomas have been classified 
according to the World Health Organization (WHO) criteria that are 
determined by histopathological examinations such as nuclear atypia, 
cellular pleomorphism, mitotic activity, vascular thrombosis, 
microvascular proliferation and necrosis [2]. Recently, in May 2016, a 
WHO reclassification of CNS tumors was established where the main 
change was the use of molecular parameters for diagnosis. Major 
restructuring of diffuse gliomas with incorporation of genetically 
defined entities was proposed [3]. This new classification is 
appropriate and makes a significant advance, because therapeutic 
targets are greatly dependent on the molecular mechanisms of 
gliomas, and tumors diagnosed in the same group have different gene 
expression profiles identified by large-scale genomic DNA analyses, 
including gene expression profiling, genome-wide association studies 
and single-nucleotide polymorphism analysis [4]. Furthermore, 
several environmental factors such as therapeutic ionising radiation, 
electrical or electronics jobs, long-term use of wireless phones, etc. 
have been correlated with an increased risk of developing gliomas. 
Genetic factors, using three signaling pathways: p53, retinoblastoma 
(RB), and receptor tyrosine kinase (RTK) play crucial roles in glioma 
development, particularly mutations in isocitrate dehydrogenase 1 
and 2, 1p and 19q co-deletion [5-7]. The identification of genetic, 
epigenetic and transcriptional abnormalities in the various types of 
gliomas helps understanding the pathogenesis, predicts prognosis 
and response to therapy and may serve as diagnostic markers. 
Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase that 
converts the inactive decapeptide angiotensin I to the vasoactive 
angiotensin II while inactivating an angiogenic agent, namely the 
vasodilator peptide bradykinin. 
  
ACE is a member of the renin-angiotensin system (RAS) expressed in 
many tissues. Several findings have shown that the ACE inhibitors 
may possibly reduce the incidence of cancer and may protect against 
it [8, 9]. Their effect on tumor cells can be attributed to their reducing 
cell proliferation and migration, inflammation and angiogenesis [8, 9]. 
Other research works reported an inhibition of the cellular matrix 
metalloprotease activity and a reduced expression of vascular 
endothelial growth factor (VEGF) by ACE inhibitors [9, 10]. The ACE 
gene is located on the band 17q23 of the 17th chromosome in 
humans. It is characterized by a major polymorphism exhibiting 
presence (I allele, insertion) or absence (D allele, deletion) of a 287-
base pair Alu repeat sequence in intron 16 of this gene [9-11]. The 
ACE I/D polymorphism is correlated to the ACE plasma 
concentrations. In patients with DD genotype, ACE's plasma and 
tissue levels are about twofold higher compared to those with II 
genotype, whereas the ID genotype indicates an intermediate level 
[9-12]. Recently, the ACE I/D polymorphism was linked to the 
pathogenesis and progression of several cancers such as lung, 
digestive, breast, laryngeal, prostate cancers and last in glioma 
[9, 13, 14]. However, the results were not often reproducible, due to 
a genetic heterogeneity factor between different populations. In a 
Dutch population based prospective cohort study that included 6670 
participants with ACE genotype, 730 incident cancer cases occurred 
during a mean follow-up time of nearly ten years [15]. Carriers of the 
high-activity genotype DD, with higher levels of ACE, had an 
increased risk of breast cancer compared with low-activity II/ID 
genotype carriers (hazard ratio (HR) = 1.47; 95% CI: 1.05-2.04), but 
no association was demonstrated for other cancers (prostate, lung 
and colorectal cancer). DD carriers who were exposed to long-term 
and high-dose of RAS inhibitors were at lower risk for cancer (HR = 
0.28; 95% CI: 0.10-0.79). Short-term, high-dose users were at risk 
for colorectal cancer progression in the II/ID stratum (HR = 3.83; 
95% CI: 1.67-8.79). In a meta-analysis including 6 studies, carriers 
of the ACE II genotype appeared to be protected from gastric cancer 
(OR 0.54-0.63, p = 0.01-0.02), regardless of ethnicity or gastric tumor 
type [16]. In a German study 88 samples from patients with early 
gastric cancer, which were obtained during gastric surgery, were 
compared with 145 blood samples from healthy controls [17]. The DD 
genotype was found significantly more often in the cancer group than 
in the healthy participants. The II genotype was associated with a 
significantly lower risk of gastric cancer than the DD genotype 
(OR=0.20, 95% CI: 0.08-0.54). Therefore, the aim of the present 
study was to evaluate the potential association between ACE I/D 
polymorphism and glioma in Algerian population and consequently on 









Subjects: the study was carried out in Constantine Ben Badis 
Hospital, involving 36 patients who were diagnosed as having glioma 
during 2016-2017 as well as 195 healthy controls which were 
matched with the glioma cases for age and sex. The controls were 
selected randomly from healthy individuals without any cancer history 
and any diseases that might have an association with the ACE I/D 
polymorphism, such as hypertension, coronary artery disease, 
diabetes mellitus and inflammatory diseases. 
  
DNA extraction and determination of the ACE I/D 
polymorphism: a volume of 10 ml of peripheral venous blood was 
extracted from all subjects and the collected samples were put into 
BD Vacutainer spray-coated K2 EDTA. Standards methods were 
followed for extraction of genomic DNA from leukocytes [18]. A 
polymerase chain reaction restriction fragment length polymorphism 
(PCR-RFLP) assay was applied to assess the ACE I/D genotypes which 
was classified as II, ID and DD. Based on the GenBank reference 
sequence, the PCR primers were as follows: forward-5'-
CTGGAGACCACTCCCATCCTTTCT-3' and reverse-5'-
GATGTGGCCATCACATTCGTCAGAT-3'. PCR reactions were performed 
in 50 μl reaction volumes with 80 pmol of each primer, 25 pmol of 
dNTP (Biomatique), 1X of 10X buffer (Biomatique), 1.5 mm of 
MgCl2 (Biomatique), 0.5 U of DNA taq polymerase (Biomatique). DNA 
amplification was performed as follows: initial denaturation step for 
1min at 94°C, followed by 30 cycles of denaturation; each step 
contained denaturation step at 95°C for 30 seconds, annealing step 
at 65.8°C for 30 sec and final extension at 72°C for 1 min. Finally, 
DNA underwent a final extension step at 72°C for 1 min. The PCR 
products had two weights of 490 and 190 bp for insertion and 
deletion, respectively. The products were first visualized by 
electrophoresis in a 2% agarose gel with ethidium bromide and finally 
in UV. 
  
Statistics: descriptive statistics were performed in terms of means 
and percentages. The bivariate analysis used contingency tables and 
chi-square test to compare the genotype distribution between the two 
groups and crude odds ratio were calculated within a 95% confidence 
interval while p-value was calculated by Fisher's exact test. P values 
were considered statistically significant if they were below 0.05. 
Statistical analysis was performed using PRISM software, version 5.5. 
  
Ethical considerations: the study was approved by an official 
review board and a declared consent was signed by patients 





Characteristics of the considered population are shown in Table 1. 
Glioma cases and controls did not differ regarding gender (p = 0.37) 
or age (p = 0.83). Mean age was similar among patients and controls 
with 44.70 ± 3.33 and 42.61 ± 5.36 years, respectively. In glioma 
cases, allelic frequencies and genotype distribution of the ACE I/D 
polymorphism were different from controls cases as shown in Table 
2. The frequency of the ACE DD genotype was higher in glioma 
patients than in controls with 63.9% and 33.8%, respectively and 
conferred 3.64-fold risk for predisposition in glioma cases (vs ID 
genotype, p<0.001). ID genotype was found with 30.6% and 59.0% 
in gliomas and in controls, respectively, II genotype with 5.6% and 
7.2%, in gliomas and in controls, respectively. Recessive model (ACE 
II + ID genotypes vs DD) was associated with a 72% reduced risk of 
glioma (OR = 0.28, 95% CI: 0.13-0.60, p<0.001) (Table 2). Likewise, 
the frequency of the allele D was higher in glioma cases than in 
controls with 79.2% and 63.3%, respectively, OR = 2.20, 95% CI: 
1.20 - 4.03, p = 0.009. The frequency of ACE I allele was 20.8% and 





As mentioned above glioma is the most common malignant tumor in 
the central nervous system which may be caused by many 
environmental, genetic or other factors. Multiple genetic and 
cytogenetic alterations have been identified in gliomas with a 
regularly increasing number. Several major molecular alterations 
have been found, such as IDH1/IDH2 (Isocitrate dehydrogenase) 
mutations in diffusely infiltrating gliomas, mutations of TP53 (tumor 
suppressor protein 53) and ATRX (Alpha-thalassemia/mental 
retardation syndrome X-linked) in astrocytomas, 1p/19q co-deletion 
in oligodendrogliomas, mutations of TERT (telomerase reverse 
transcriptase) promoter in oligodendrogliomas and IDH wild-type 
glioblastomas, and mutations or fusions of BRAF in circumscribed 
astrocytomas [19]. Identification of those and several other genetic 
abnormalities is very important and may help to determine 
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appropriate treatment and to predict prognosis. Otherwise, recently, 
many mechanisms to explain tumorigenesis known as the "hallmarks" 
of cancer have been proposed [20] and they are connected to many 
biochemical pathways including the RAS whose role in CNS tumors 
has led to an increasing interest among researchers. Classically, the 
RAS has been studied as a fundamental component of cardiovascular 
homeostasis, playing a critical role in cardiovascular system, balance 
of water and electrolytes and cell growth [8, 21, 22]. However, RAS 
also is expressed in several tissues and organs (liver, kidneys, 
pancreas, reproductive organs, and brain). Some of these local effects 
are related to carcinogenesis and gliomagenesis [8]. The perturbation 
of RAS components plays a significant role in the proliferation, 
angiogenesis, and invasion of these tumors. Angiotensin II can 
stimulate tumor neovascularization [23], and over expressions of ACE 
and angiotensin II type 1 receptor have been associated with tumor 
growth, metastasis, and progression [24-26]. The ACE gene I/D 
polymorphism has been linked to many cancers with a very few 
researches on glioma. The present study was interested in potential 
association between ACE I/D polymorphism and glioma in Algerian 
population. The main result indicated a strong association between 
this polymorphism and the risk of glioma. A recessive model was 
associated with a 72% reduced risk of glioma (p<0.001). Likewise, 
the DD genotype predisposed risk of glioma by more than 3-fold i.e. 
63.9 and 33.8% in glioma cases and controls, respectively (p<0.001), 
indicating the potential of ACE I/D polymorphism as a predictive 
marker in glioma. We also found that the risk conferred by a per copy 
allele D is 2.2-fold for glioma cases. Frequency of D allele was higher 
in glioma cases than in controls (79.2% and 63.3%, respectively, p = 
0.009). Those results are supported partly by the first report 
describing the potential association between ACE I/D polymorphism 
and glioma in Chinese population. In this study, glioma cases had a 
significantly higher frequency of DD genotype (OR = 1.61, 95% CI = 
1.12, 2.32; p = 0.01) than controls [13]. But the frequency of D allele 
was similar in glioma cases and in controls (30.9% vs 28.3%, p = 
0.1) 
  
In another recent study in Indian population: ACE DD genotypes were 
highly presented in glioma cases compared to controls with 26.8% 
and 10.6%, respectively (p<0.0001) and conferred 5-fold risk for 
predisposition in glioma cases. Per copy D allele frequency was found 
higher in glioma cases than in controls (54% and 25%, respectively, 
p<0.0001) [14]. No similar studies were found in North Africa. For 
instance, a Moroccan study summarized 3 research works with 65, 62 
and 34 patients, on the frequency of altered genes in patients with 
glioblastoma, where only alteration of IDH1/2, p53 and EGFR 
expression were analysed [27]. The frequency of these gene mutation 
in Moroccan population was similar to those reported from other 
populations. In Tunisian population with glioma, genetic analysis in 
110 cases of glioma assessed 10q LOH including PTEN as the most 
frequent chromosome alteration [28]. Moreover, the impact of studies 
on ACE I/D polymorphism in glioma was also therapeutic. The results 
in the Rotterdam study concerning a prospective cohort with 7983 
participants, showed that RAS inhibitors seemed to protect against 
cancer in patients with the ACE DD genotype [15]. Indeed, ACE's 
plasma and tissue levels were higher in subjects with DD genotype, 
compared to those with II or ID genotypes and its activity can be 
blocked by ACE inhibitors [9, 12]. Their effect on tumor cells could be 
attributed to their reducing cell proliferation and migration, 
inflammation and angiogenesis, inhibition of the cellular matrix 
metalloprotease activity and a reduced expression of VEGF (8-10). 
Finally, it should be recognized that the current study was the first 
one in the middle east and north Africa (MENA) region, that had 
investigated the association between ACE I/D polymorphism and 
glioma, bearing in mind the potential application of the RAS 
components as biomarkers or treatment targets in glioma. However, 
it should be precised that only the Eastern population of Algeria was 
concerned by the present study which then cannot be considered as 
fully representative of the entire country population. Although the size 
of the population was small due to the fact that this pathology is 
relatively rare in Algeria, with about 1 percent only of all cancers 
(unpublished data from the Constantine University Hospital), the 
number of cases was consistent for a statistical analysis to obtain 
useful results and to define the orientation to be given to further 
studies. Nevertheless, a study with a large sample and a follow-up 






The obtained data suggest that the ACE I/D polymorphism could be 
a risk factor for glioma. However, this has to be confirmed with 
additional studies considering large samples of different ethnical 
groups. 
 
What is known about this topic 
 The ACE gene I/D polymorphism has been linked to many 
cancers; 
 
Page number not for citation purposes     5 
 
 Recently, only 2 reports had shown the relationship 
between this polymorphism and glioma. 
What this study adds 
 The ACE I/D polymorphism could be a risk factor for glioma 
or predictive marker; 
 Renin-angiotensin system blockade may be used in a future 
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Table 1: characteristics (mean ± SD or %) of Algerian population with 
glioma and healthy controls 
  Cases n (%) Controls n (%) p 
Total 36 (100) 195 (100) 
 
Age (years) 44.70  ± 3.33 42.61 ± 5.36 0,83 
Gender 
   
Males 23 (63.9) 109 (55.9) 0.37 
Females 13 (36.1) 86 (44.1) 
 
Smoking status 
   
Non-smoking 30 (83.3) 189 0.007 
Active smoking 5 (13.9) 5 0.002 
Passive smoking 1 (2.8) 1 0.18 
Family history of 
glioma 




















Table 2: ORs and 95% CIs of the association between ACE I/D polymorphism and glioma risk 
Model Cases (n) Controls (n) OR p 
Homozygous co-
dominant: DD vs II 
    
DD 23 66 2.43 (0.51-11.55) 0.24 
II 2 14 
  
Heterozygous co-
dominant: ID vs II 
    
ID 11 115 0.66 (0.13 -3.33) 0.62 
II 2 14 
  
Heterozygous co-
dominant: DD vs ID 
    
DD 23 66 3.64 (1.67-7.94) <0.001 
ID 11 115 
  
Dominant model: (DD 
+ ID) vs II 
    
DD + ID 34 181 1.31 (0.28-6.04) 0.7 
II 2 14 
  
Recessive model: (II 
+ ID) vs DD 
    
II + ID 13 129 0.28 (0.13-0.60) <0.001 
DD 23 66 
  
Allele model 
    
D 57 247 2.20 (1.20-4.02) 0.009 
I 15 143 
  
